SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue guidance is driving attention, with traders welcoming the update as a sign of strengthening Amtagvi demand and commercial growth. The community is also looking ahead to NSCLC data, while takeover and short-squeeze theories remain speculative.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop next-generation 10 kV silicon-carbide devices is the main catalyst, with traders viewing it as technology and domestic-manufacturing validation. The reaction is tempered by uncertainty over near-term revenue because it is a prototype program with undisclosed financial terms, alongside frustration over the stocks pullback and broader semiconductor weakness.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas agreed $2 billion equity investment in Summit, paired with a clinical-trial collaboration for ivonescimab, is driving attention. Traders view the deal as a vote of confidence and relief on funding, while others caution it is not an acquisition and does not resolve the upcoming FDA decision; buyout and short-squeeze talk remains speculative.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes allowing VantageScore alongside FICO for eligible mortgagesand Rocket Mortgages plan to default to VantageScore for eligible loansare fueling concern that competition could erode FICOs longstanding mortgage-scoring advantage. Traders debate whether the selloff reflects lasting pressure on its moat and pricing power or an overreaction, with some seeking a dip-buying opportunity.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp ZBCN rally has sparked breakout and resistance chatter, while some traders speculate about a Robinhood connection; that partnership talk remains unconfirmed. Reactions are divided between bullish momentum and skepticism that the move may fade like previous pumps.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

Traders are focused on uniQures four-year AMT-130 data for Huntingtons disease, with bullish anticipation for evidence of sustained benefit and concern that the readout could disappoint. Debate also centers on the companys BLA filing based on earlier data and what the longer-term results could mean for the therapys regulatory prospects.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Kodiaks positive late-stage wet AMD results have pressured OCUL as traders weigh the rivals durability data against AXPAXLI. Many bulls argue differences in trial design and AXPAXLIs longer-duration profile make the selloff excessive, while skeptics see stronger competition raising the bar.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Rising Treasury yields and weakness across semiconductor shares are weighing on SMH, while traders debate whether the pullback is a technical pause or a deeper rotation away from chip stocks. Bullish voices point to continued AI infrastructure demand and sector strength; bearish voices cite rate pressure, stretched AI spending, and fragile charts.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Traders are focused on an upcoming NXC-201 clinical-data update in relapsed/refractory AL amyloidosis, with bullish expectations for continued strong responses tempered by uncertainty ahead of the readout. The discussion also weighs the impact of a recent share offering against optimism about the trial results.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Starships first orbital flight and deployment of next-generation Starlink satellites is the main focus, with bullish traders viewing it as a milestone for expanding Starlink capacity and launch scale. Skeptics point to engine trouble and the shortened mission, while others question why the stock fell despite the achievement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


andrewperlstein

Andrew Perlstein